Global Iron Chelation Drug Market Study 2015-2025, by Segment (Deferoxamine, Deferiprone, Deferasirox), by Market (Transfusional Iron Overload, NTDT Caused Iron OverloadDeferiprone), by Company (Apotex Inc. (Canada), Cipla (India), Novartis (Switzerland))

September 2018 | 71 pages | ID: G89EA9DD193EN
99Strategy

Abstracts

SNAPSHOT

The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.

The global Iron Chelation Drug market will reach xxx Million USD in 2018 and with a CAGR if xx% between 2019-2025.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

• Deferoxamine
• Deferiprone
• Deferasirox

Demand Coverage (Market Size & Forecast, Consumer Distribution):

• Transfusional Iron Overload
• NTDT Caused Iron Overload

Company Coverage (Sales data, Main Products & Services etc.):

• Apotex Inc. (Canada)
• Cipla (India)
• Novartis (Switzerland)
• Sun Pharma (India)
• Natco Pharma (India)

Major Region Market

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Contents

1 INDUSTRY OVERVIEW

1.1 Iron Chelation Drug Industry
  1.1.1 Overview
  1.1.2 Products of Major Companies
1.2 Market Segment
  1.2.1 Industry Chain
  1.2.2 Consumer Distribution
1.3 Price & Cost Overview

2 IRON CHELATION DRUG MARKET BY TYPE

2.1 By Type
  2.1.1 Deferoxamine
  2.1.2 Deferiprone
  2.1.3 Deferasirox
2.2 Market Size by Type
2.3 Market Forecast by Type

3 GLOBAL MARKET DEMAND

3.1 Segment Overview
  3.1.1 Transfusional Iron Overload
  3.1.2 NTDT Caused Iron Overload
3.2 Market Size by Demand
3.3 Market Forecast by Demand

4 MAJOR REGION MARKET

4.1 Global Market Overview
  4.1.1 Market Size & Growth
  4.1.2 Market Forecast
4.2 Major Region
  4.2.1 Market Size & Growth
  4.2.2 Market Forecast

5 MAJOR COMPANIES LIST

5.1 Apotex Inc. (Canada) (Company Profile, Sales Data etc.)
5.2 Cipla (India) (Company Profile, Sales Data etc.)
5.3 Novartis (Switzerland) (Company Profile, Sales Data etc.)
5.4 Sun Pharma (India) (Company Profile, Sales Data etc.)
5.5 Natco Pharma (India) (Company Profile, Sales Data etc.)

6 CONCLUSION

List Of Tables

LIST OF TABLES

Table Global Iron Chelation Drug Market 2015-2018, by Type, in USD Million
Table Global Iron Chelation Drug Market 2015-2018, by Type, in Volume
Table Global Iron Chelation Drug Market Forecast 2019-2025, by Type, in USD Million
Table Global Iron Chelation Drug Market Forecast 2019-2025, by Type, in Volume
Table Apotex Inc. (Canada) Overview List
Table Iron Chelation Drug Business Operation of Apotex Inc. (Canada) (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Cipla (India) Overview List
Table Iron Chelation Drug Business Operation of Cipla (India) (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Novartis (Switzerland) Overview List
Table Iron Chelation Drug Business Operation of Novartis (Switzerland) (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Sun Pharma (India) Overview List
Table Iron Chelation Drug Business Operation of Sun Pharma (India) (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Natco Pharma (India) Overview List
Table Iron Chelation Drug Business Operation of Natco Pharma (India) (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)

List Of Figures

LIST OF FIGURES

Figure Global Iron Chelation Drug Market Growth 2015-2018, by Type, in USD Million
Figure Global Iron Chelation Drug Market Growth 2015-2018, by Type, in Volume